What Peptides Are Really Doing to Your Body
The reassurance about peptides is that the danger lives in the supply chain: buy clean, and the risk is gone. It is not. They have side effects when the vial is exactly what it claims, and for many the long term picture is blank.
The Evidence Gap
For most of these peptides the human data is thin, from animal or small, short trials. The ones that take months or years need long term research, mostly not done. MK-677, sold on a multi year safety record, was tested in healthy adults in their 60s and 70s, not young lifters.
The Growth Hormone Peptides
CJC-1295, ipamorelin, sermorelin, and oral MK-677 push the body to release more growth hormone and, downstream, more IGF-1. Documented effects are consistent: fluid retention, appetite, broken sleep, joint pain. MK-677 is the clearest: water retention, some of the "lean" gain being water not muscle, plus rising fasting glucose and falling insulin sensitivity. One frail elderly trial stopped early over a heart failure signal.
The Healing Peptides
BPC-157 and TB-500 are the recovery favorites; the problem is no human evidence: findings almost all from rodents, human data little more than one small BPC-157 knee study. What exists flags immunogenicity, an immune reaction to the peptide. Benefits unproven, long term risks unmeasured.
The Cosmetic and Libido Peptides
Melanotan is tied to nausea, flushing, and the darkening of moles and new ones, which dermatologists take seriously: it raises melanoma concern and hides skin cancer. Bremelanotide (PT-141) is similar.
The IGF-1 Problem
The most evidence backed concern is a mechanism, not a side effect, common to every peptide that raises IGF-1: a growth signal that drives cells to multiply and blunts apoptosis. In animals, high IGF-1 raises tumor rates and low IGF-1 lowers them.
Across pooled prostate studies, men with high IGF-1 ran about 1.5 times the risk of low levels; in the Physicians' Health Study the top quartile carried five times the risk of advanced prostate cancer. A pooled analysis of 17 prospective studies and nearly 5,000 cases put women with high IGF-1 at around 30 percent greater breast cancer risk.
None of that proves a user gets cancer, only that chronically raising the marker these compounds raise moves you toward a profile large studies tie to higher risk.
The Bottom Line
The unknowns, especially sustained IGF-1 elevation, are real and unstudied. Anything active enough to change your body is active enough to carry a cost.
If you pursue peptides anyway, the only data informed path is supervision: a physician tracking fasting glucose, insulin, and IGF-1. A clean vial does not touch the physiology, where the real questions live.
This article is educational and is not medical advice. The long-term safety of most peptides discussed here has not been established in humans. Do not start, stop, or combine any peptide, medication, or supplement without guidance from a qualified healthcare provider who can evaluate your individual risks and monitor the relevant bloodwork.
Copyright 2026 The Arena Group, Inc. All Rights Reserved
This story was originally published June 22, 2026 at 4:35 PM.